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Abstract: Expression quantitative trait loci (eQTL) can provide a link between disease susceptibility
variants discovered by genetic association studies and biology. To date, eQTL mapping studies have
been primarily conducted in healthy individuals from population-based cohorts. Genetic effects have
been known to be context-specific and vary with changing environmental stimuli. We conducted a
transcriptome- and genome-wide eQTL mapping study in a cohort of patients with idiopathic or
heritable pulmonary arterial hypertension (PAH) using RNA sequencing (RNAseq) data from whole
blood. We sought confirmation from three published population-based eQTL studies, including the
GTEx Project, and followed up potentially novel eQTL not observed in the general population.
In total, we identified 2314 eQTL of which 90% were cis-acting and 75% were confirmed by at least
one of the published studies. While we observed a higher GWAS trait colocalization rate among
confirmed eQTL, colocalisation rate of novel eQTL reported for lung-related phenotypes was twice as
high as that of confirmed eQTL. Functional enrichment analysis of genes with novel eQTL in PAH
highlighted immune-related processes, a suspected contributor to PAH. These potentially novel eQTL
specific to or active in PAH could be useful in understanding genetic risk factors for other diseases
that share common mechanisms with PAH.
Keywords: expression quantitative trait locus; eQTL; pulmonary arterial hypertension; blood; genetics
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1. Introduction
The relationship between genomic variability, disease risk and endophenotypes has been a focus
of many research groups with access to suitable disease cohorts. This has been aided by the increasing
affordability of genotyping and sequencing methodologies. Interpretation of the mechanisms behind
the effects of genetic variants discovered to associate with phenotypes poses a challenge as many
are located in the non-coding space of the genome [1]. Non-coding variants exert no direct effect on
protein structure, making the biological link to the disease or phenotype more difficult to discern.
Variants in the non-coding space may instead exert their effect by influencing gene expression [1].
Characterising the genomic control of gene expression can offer a handle on understanding the role of
disease-associated variants by linking them to disrupted pathways [2]. Variants associated with the
expression of a gene, commonly called expression quantitative trait loci (eQTL), have been described,
primarily in population-based studies [3–5].
Differential gene expression analyses comparing cases and controls may be useful for diagnostic
and/or prognostic purposes or in identifying genes, which may have a causal role in developing the
disease [6–8]. In the case of the latter, distinguishing between differentially expressed genes that are
secondary to the disease and those that contribute to disease development is a significant challenge.
If the frequency of one or several eQTL for a differentially expressed gene is also different between cases
and controls, a causal association may be established, given the assumptions of causal inference [9] are
met. In brief, for a causal relationship to be established between a gene product proxied by an eQTL
and a disease, the eQTL has to be independent of the confounders of the association between the gene
and the disease, and it has to have no direct effect on the disease via a pathway that does not involve
the gene being instrumented.
Currently, one of the main limiting factors for causal inference analysis using genomic data is the
number of known eQTL. Certain eQTL effects, which go undetected in healthy cohorts commonly
used for eQTL mapping, may be unmasked by disease and development. The diagnostic value of gene
expression profiles, i.e., that they can be used to distinguish affected individuals from non-affected
ones, underlines the uniqueness of the set of genes expressed in a disease state [6,7]. Differential gene
expression in diverse states (carcinogenesis, inflammation, etc.) or at diverse stages (such as stages of
embryonic development) becomes evident when comparing the gene correlation matrices of a biological
system under multiple different conditions. Such techniques are called ‘differential co-expression
networks’ [10] and have been used successfully to identify genes and gene sets that are important in
the state or stage under investigation in a network of genes [11,12]. By principle, functionally involved
nodes or modules rewire more frequently than uninvolved ones in states they create and/or maintain
and, therefore, can be identified [13].
With the exception of housekeeping genes, the majority of genes in the human transcriptome
are tissue-specific. Therefore, tissue selection for gene expression studies of disease is of importance.
The lung is the most relevant tissue in the pathogenesis of pulmonary arterial hypertension (PAH),
a disease in which pulmonary vascular remodelling drives right ventricular failure. Whole blood also
has relevance to PAH and might capture more than just systemic effects given the immune component of
this disease. The role of inflammation in PAH has been extensively studied, based on the observation that
inflammatory cells infiltrate the remodeled vascular wall [14]. Since PAH can be a complication of many
inflammatory diseases, including connective tissue disease, thyroiditis, scleroderma, systemic lupus
erythematosus, human immunodeficiency virus infection and schistosomiasis, it might be reasonable
to suspect that inflammatory processes, even in the absence of a diagnosed comorbidity, contribute to
disease development and maintenance. Another advantage of using whole blood instead of lung tissue
is the non-invasiveness of sampling and availability. Lung samples are often only obtainable from the
explanted organ after lung transplantation or from post-mortem tissues. Appropriate control samples
for differential gene expression analyses are equally hard to come by.
This study aimed to characterise the genetic variability of transcriptome-wide gene expression in
whole blood from 276 consecutively sampled patients with PAH and defined potentially novel eQTL
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active in this disease state. These potentially disease-specific eQTL could be useful in elucidating
known genotype-phenotype associations or causal analyses.
2. Materials and Methods
2.1. Study Participants and Sample Processing
A total of 276 patients with idiopathic, heritable or drug-induced PAH diagnosed following
international guidelines [15] were recruited from expert centres across the UK with whole-genome
sequence conducted as part of the UK National Institute for Health Research BioResource (NIHRBR)
study [16,17]. Transcriptome profiling through RNAseq was completed as part of the PAH cohort
study [18]. Demographic characteristics and white blood cell counts of the individuals in this study
are shown in Supplementary Table S1.
2.2. Gene Expression Data
RNA sequencing and transcript abundance estimation procedures are described in the
Supplementary Material. White blood cell composition was quantified using quanTIseq, a novel
deconvolution algorithm [19]. Predicted white blood cell fractions from quanTIseq correlated with
clinical white cell fractions available in a subset of PAH patients (Spearman correlation = 0.44–0.73).
Well-detected transcripts with a minimum of two reads in at least 95% of samples (n = 26,050) were
taken forward to the eQTL analyses.
2.3. Genetic Data
Whole-genome sequence Hg19-aligned data were available from the NIHRBR study described in
detail elsewhere [16]. Genetic variants with a minimum minor allele frequency of 5% were extracted
from the NIHRBR variant call format (VCF) files and further filtered for variants called in at least
95% of the samples and had a p-value greater than 10−5 for Hardy Weinberg equilibrium, leaving a
total of 7,362,566 variants for eQTL mapping. Software tools used in the eQTL mapping pipeline
included PLINKv1.90 [20] for data extraction and computing multidimensional scaling components,
QCTOOLv2.0 [21], for variant filtering, and QUICKTESTv1.1 [22] for association testing.
2.4. eQTL Effect Estimation
Raw gene count data were first variance stabilised to achieve homoskedasticity and then quantile
normalised to the median distribution. The sample means were then centered to zero, and the sample
variance was linearly scaled, such that each sample had a standard deviation of one. A total of 7,362,566
markers were tested for their effects on the expression of 26,050 well-detected genes. Variants within
1 megabase (Mb) on either side of the gene’s transcription start site (TSS) were regarded cis-acting or
cis-eQTL while all other markers farther on the same chromosome or on different chromosomes were
regarded trans-eQTL. Each well-detected transcript was modelled as a function of genotype (coded 0, 1
or 2 reflecting the number of alternate alleles) in a linear regression framework while adjusting for the
following covariates: Sex, first four components from multidimensional scaling and white blood cell
fractions (Supplementary Table S1). The genome-wide results were subsequently pruned using the
‘clump’ command in PLINK 1.90 (parameters: —clump-p1 1.9 × 10−12; —clump-r2 0.01; —clump-kb
1000) to pick the lead variant with the lowest p-value in a block of variants in linkage disequilibrium,
and thus obtain independent effects. Genetic variants that reached the Bonferroni-adjusted significance
threshold of 1.9 × 10−12 given by dividing the genome-wide significance threshold (p ≤ 5 × 10−8) by
the number of transcripts tested (n = 26,050) were considered eQTL in this study.
2.5. Confirmation Rate
The confirmation rate of eQTL in this study was calculated in the 2 largest published eQTL studies
to date and the Genotype-Tissue Expression (GTEx) Project [3,4,23] (Table 1) to assess the extent to which
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eQTL in PAH overlapped with eQTL described in healthy populations. These studies were selected for
having measured gene expression in the same tissue as our study, in addition to being the largest eQTL
mapping studies to date. No eQTL study other than the GTEx Project with available genome-wide
results applied RNAseq in whole blood at the time this study was conducted. Confirmation rate
was defined as the number of PAH eQTL confirmed by the published study, divided by the total
number of PAH eQTL tested by the published study and multiplied by 100 to give a percent value.
The matching of gene transcripts and genetic variants between our study and the published studies as
well as similarities and differences between the designs of this study and the 3 published studies are
described in Table 1 and in the Supplementary Appendix.
Table 1. Characteristics of the PAH Cohort eQTL mapping study and published eQTL studies used
for confirmation.
Westra et al. Joehanes et al. GTEx This Study
Gene expression array Illumina HumanHT-12 v4.0 Affymetrix HuEx 1.0 ST RNAseq RNAseq
Genotyping panel HapMap2 1000-Genomes WGS WGS
MAF threshold ≥5% ≥1% ≥1% ≥5%
n variants in analysis not reported 8,510,936 10,008,325 7,362,566
cis-eQTL ≤250 kb from PMP ≤1 Mb from the TSS ≤1 Mb from the TSS ≤1 Mb from the TSS
trans-eQTL ≥5 Mb from PMP >1 Mb from the TSS >1 Mb from the TSS >1 Mb from the TSS
Comparison of gene expression- and genetic data and expression quantitative trait locus (eQTL) definitions. MAF =
minor allele frequency; PMP = probe midpoint; TSS = transcription start site; RNAseq = RNA sequencing; WGS =
whole-genome sequencing.
2.6. Overlap with Variants from the GWAS Catalog
An important aim of this study was to identify eQTL in PAH with effects that had not been
observed in population-based studies and to assess the relevance of these PAH-specific eQTL to related
phenotypes and diseases. The NHGRI-EBI GWAS Catalog of published genome-wide association
studies (GWAS) [24] provided a curated database of genetic markers associated with a wide range of
traits and diseases. All variant-phenotype pairs below an association p-value threshold of 9 × 10−6
were downloaded from the GWAS Catalog website on 5 March 2020. The GWAS Catalog at the time
contained 113,510 unique variants (including variants in linkage disequilibrium [LD]) reported as
lead variants for 4314 phenotypes. The list of GWAS variants were intersected with each PAH eQTL
(including the lead eQTL and variants in LD with the lead eQTL [r2 ≥40%]). The difference between the
proportions of novel eQTL and previously reported eQTL overlapping lung-related phenotypes and
diseases curated from the full GWAS Catalog phenotype list was tested using the 2-sample equality of
proportions test.
2.7. Functional Enrichment Analysis of Genes with Novel eQTL
Functional enrichment analysis of genes with novel eQTL in PAH using the WEB-based GEne
SeT AnaLysis Toolkit (WebGestalt) [25] was conducted to determine if genes with novel eQTL were
predominantly from pathways with relevance to the pathobiology of PAH. A form of pathway analysis
called over-representation analysis (ORA) [26] was run using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways [27] database to group these genes into a smaller number of gene-sets
relating to biological processes. We queried the list of genes with novel eQTL whilst all the tested
genes also present on the expression array of at least one of the published eQTL studies used for the
confirmation process constituted the list of background genes. Pathways below a false-discovery rate
(FDR)-corrected significance threshold of 0.05 were considered significant.
3. Results
We observed 2354 eQTL in total with the majority (90%) acting in cis (Figure 1A), accounting for 9%
of all genes tested in this transcriptome- and genome-wide eQTL mapping analysis in PAH whole blood
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samples. Of these eQTL, 146 were associated with unmapped transcripts not yet annotated in the Ensembl
database (Figure 1B). Lead eQTL ranked by the percent of variance explained (R2) in gene expression are
presented in the Supplementary Table S2. The proportion of variation explained (R2) in gene expression
levels was generally lower for trans-eQTL than for cis-eQTL (mediancis-eQTL = 23.1%, IQRcis-eQTL = 12.5%;
mediantrans-eQTL = 21.5%, IQRtrans-eQTL = 11.5%; t(df=1332) = 4.5, p-value = 8.3 × 10
−6).
 
ƺ
(A) 
 
(B) 
Figure 1. (A) Results of the pulmonary arterial hypertension (PAH) Cohort eQTL mapping. Genomic
eQTL location (x-axis) plotted against the transcription start site of the gene associated with the eQTL.
Bubble size and color are proportional to the effect size of the eQTL-gene association. (B) Pie chart
showing the proportions of cis-, trans- and unmapped eQTL identified in the PAH Cohort eQTL
mapping. Counts of eQTL within each category are shown next to the category name. An eQTL was
considered ‘novel’ if it was eligible to be confirmed in at least one of the previously published studies
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and was not reported as an eQTL previously. Those eQTL that reached the study-specific significance
threshold in at least one of the published studies were considered ‘confirmed’. Unmapped transcripts
not yet annotated in the Ensembl database could not be confirmed. Ineligible eQTL were not tested by
any of the three studies used for confirmation.
3.1. Confirmation Rate
Out of the 1986 unique genes with cis-eQTL, 1509 (76%) could be mapped to the Illumina HT12v3
array used by Westra et al. and 2134 (95%) to the Affymetrix Human Exon chip used by Joehanes et al.,
respectively. Results from the GTEx Portal were obtained for 73% of eQTL in this study. Twenty-eight
percent of cis-eQTL were confirmed by Westra et al., 31% by Joehanes et al. and 90% of tested cis-eQTL
confirmed in GTEx. Overall, 75% of cis-eQTL were confirmed in at least one of the published studies
(Figure 1). The overall confirmation rate for trans-eQTL reached 16%, with all but one being confirmed
by GTEx alone. Joehanes et al. confirmed only one trans-eQTL for JAM3 (chr1:248039451 [C/T]).
3.2. Overlap with Variants from the GWAS Catalog
In order to assess the relevance of eQTL identified in this study to a wide range of phenotypes and
diseases, the 2173 unique eQTL were intersected with the database of published genotype-phenotype
associations from the GWAS Catalog. In total, 929 eQTL were reported for at least one trait previously
(medianN GWAS traits/eQTL = 2; IQRN GWAS traits/eQTL = 3). Ninety-eight (11%) of the 929 eQTL had at
least 10 or more unique GWAS phenotypes associated with them. Figure 2 shows the number of
overlapping GWAS phenotypes per eQTL in the confirmed and novel eQTL categories. The proportion
of cis-acting eQTL overlapping with at least one published GWAS association in the confirmed subset
was 47%, while in the novel subset, it was 37%. Among trans-eQTL, the proportion of loci overlapping
at least one GWAS trait was 50% in the confirmed and 27% in the novel group. The higher proportion
of overlapping loci in the confirmed eQTL groups was significant for both cis- and trans-acting eQTL
(two-sample equality of proportions test cis-eQTL: χ2(df=1) = 13.9; 95% CI = 0.05–0.15; p-value =
0.0002. trans-eQTL: χ2(df=1) = 4.2; 95% CI = −0.003–0.45; p-value = 0.04). Interestingly, the proportion
of novel eQTL previously reported for lung-related phenotypes (11%) was twice as high as the
proportion of confirmed eQTL associated with lung-related phenotypes (5.5%) (χ2(df=1) = 6.9; 95% CI =
0.006–0.1; p-value = 0.009). Lung-related phenotypes reported for the novel eQTL included chronic
obstructive pulmonary disease (COPD), lung function (forced vital capacity, forced expiratory volume),
low versus high forced expiratory volume, interstitial lung disease, emphysema, lung cancer and lung
adenocarcinoma. The full list of 63 QTL overlapping lung-related phenotypes in the GWAS Catalog
can be found in Supplementary Table S3.
 
Λ
Λ ƺ
Λ
Figure 2. GWAS trait-associations reported for eQTL in the PAH Cohort. Percentage of binned
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numbers of overlapping GWAS traits (y-axis) per eQTL in each eQTL category (x-axis). Reported
genotype-trait associations were downloaded from the NHGRI-EBI Catalog of published genome-wide
association studies.
3.3. Functional Enrichment Analysis of Genes with Novel eQTL
We assessed the list of 606 genes with novel eQTL in the PAH Cohort for their involvement in
certain biological processes or pathways in the KEGG knowledgebase. Five pathways were found to
be significantly (FDR <0.05) enriched, with the pathways taste transduction, graft-versus-host disease
and autoimmune thyroid disease being the three most significant (Table 2). Supplementary Table S4
lists the overlapping genes driving the association of these five pathways and our results with the
corresponding eQTL in PAH, including several human leukocyte antigen (HLA) genes. Furthermore,
all genes overlapping with type I diabetes and allograft rejection pathways come from the HLA class.
Genes encoded by the more than 200 HLA genes in the highly polymorphic HLA region play an
important role in antigen processing and presentation. In total, 20 genes with eQTL in this study
came from the HLA classes I and II (n = 18) and from the HLA class IB (n = 2) genes. Half of these
eQTL-HLA gene associations were found to be novel. Out of the 5 trans- and 17 cis-eQTL, 3 trans- and
8 cis-eQTL were confirmed by published studies [3,4,23].
Table 2. Pathways enriched for genes with novel eQTL in the PAH Cohort.
Gene Set Description Size Overlap Expectation Enrichment Ratio p-Value FDR
hsa04742 Taste transduction 48 8 0.87 9.24 1.78 × 10−6 5.72 × 10−4
hsa05332 Graft-versus-host disease 32 6 0.58 10.40 1.85 × 10−5 2.86 × 10−3
hsa05320 Autoimmune thyroid disease 34 6 0.61 9.79 2.66 × 10−5 2.86 × 10−3
hsa05330 Allograft rejection 33 5 0.59 8.40 2.75 × 10−4 0.02
hsa04940 Type I diabetes mellitus 36 5 0.65 7.70 4.19 × 10−4 0.03
Results of the over-representation analysis using the Kyoto Encyclopedia of Genes and (KEGG) pathway database.
Column names: Gene set = searchable identifier of the gene set in KEGG; Size = number of genes participating in the
gene set and overlap gives the number of genes in the gene set that overlap with the queried gene list; Expectation =
number of genes that are expected to be shared between the queried gene list and the gene set if the queried list was a
random sample of the background gene list; Enrichment ratio = fold enrichment of the gene set for the queried gene
list; p-value = enrichment significance of the Fisher‘s exact test; FDR = false discovery rate adjusted significance.
4. Discussion
Gene expression serves as an intermediate phenotype between genetic variants and associated
phenotypes, such as clinical diagnoses, accepted biomarkers and anthropometric and behavioural
traits. Previous eQTL studies provided support for the idea that genetic effects on gene expression
have phenotypic consequences and that eQTL aid in the biological interpretation of associated genetic
markers in disease [3–5]. However, eQTL effects are not only dependent on the tissue or cell type
under investigation [23,28] but also on the environment or context [5,29–31] in which gene expression
is measured. This implies that a more comprehensive eQTL map could be constructed by extending
mapping efforts beyond population-based studies. We ran a transcriptome-wide eQTL analysis in a
cohort of 276 PAH patients to characterise the genetic control of gene expression variability in this
condition, uncovering potentially novel eQTL not detected in healthy populations. The resulting 2354
significant eQTL were intersected with the results of two previously published population-based eQTL
studies and the results of the GTEx Project. In this study, 25% of cis-eQTL and 84% of trans-eQTL were not
found in any of the three studies used for confirmation. Novel and confirmed eQTL were investigated
for their relevance to a wide range of diseases, and results focused on lung-related phenotypes from
the NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog).
Nearly half (43%) of all eQTL identified in this study colocalised with at least one trait or disease
in the GWAS Catalog. Even though the proportion of colocalising eQTL was higher for confirmed cis-
and trans-eQTL than for novel eQTL, the proportion of eQTL associated with lung-related phenotypes
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was twice as high among novel eQTL than confirmed eQTL previously detected in population-based
studies. This indicates that these novel eQTL identified in blood samples of PAH patients might be
highly informative for pulmonary diseases such as COPD, interstitial lung disease and emphysema.
The higher proportion of GWAS-trait associated eQTL in the confirmed subset might be explained by
the lack of replication of novel eQTL by an independent PAH cohort; therefore, it is expected that a
proportion of these novel association signals is spurious.
As an example for the overlap between lung-related GWAS traits and eQTL in PAH, the novel
GTF2IRD2B cis-eQTL rs13238996 (Supplementary Table S3) overlaps with multiple phenotypes
including COPD [32], lung function [33], cardiovascular disease [33] and diastolic blood pressure [34].
The Deletion of GTF2IRD2B leads to a rare congenital disease called Williams-Beuren syndrome,
which frequently presents with supravalvular aortic stenosis (SVAS; OMIM 185500), a congenital heart
defect characterised by the narrowing of the aorta, pulmonary and coronary arteries and other blood
vessels [35].
Pathway analysis of genes associated with novel eQTL identified five biological processes,
including four immune-related phenotypes enriched for this list of genes from the KEGG database.
Six genes from the graft-versus-host disease and allograft rejection pathways overlap with the list
of genes with novel eQTL, five of which belong to the Human Leukocyte Antigen (HLA) class.
The immune-related pathways enriched for genes with novel eQTL in this study demonstrate that
novel eQTL could be identified in disease populations since their gene expression profiles differ from
the profiles of healthy individuals. The complex pathophysiological mechanisms behind PAH involve
multiple driving factors of which immune dysfunction and inflammation are suspected to be among
the major contributors (Rabinovitch et al., 2014). The importance of antigen-presenting and recognition
in PAH is underlined by the most significant genetic variant discovered in the PAH GWAS in the
HLA-DPA1/DPB1 locus encoding class II major histocompatibility complex (MHC) molecules [16],
which associated with three HLA-DPB1 alleles, all containing a glutamic acid at amino acid residue 69
(Glu69). The HLA-DPA1/DPB1 PAH susceptibility locus emphasises the role of immune dysregulation
in PAH development [36,37] and warrants further investigation.
Overall, the confirmation rate of eQTL in this study was comparable to that seen in published
studies [3,4]. A third of cis-eQTL confirmed in the two population-based studies by Westra et al.
and Joehanes et al., while 90% of cis-eQTL were confirmed by the GTEx Project. Fifteen percent of
trans-eQTL confirmed in either the GTEx project or the study of Joehanes et al. Trans-eQTL validation
rates are generally much lower (under 10%) than validation rates of cis-eQTL [3,4], reflecting the higher
average effect size of cis-eQTL and a stronger tissue-specificity of trans-eQTL effects compared to
cis-eQTL, which may render trans-eQTL more susceptible to confounding by differing experimental
conditions and environmental factors. However, the confirmation rate reported by this study and
other studies possibly underestimate the true extent of eQTL overlap between studies since the list
of variants and genes that passed quality control and were tested by any one study are usually not
made available. We observed a higher confirmation rate with the GTEx Project that also used RNAseq
for assaying gene expression. Similarly, Joehanes et al. reported higher validation rates between two
array-based studies than between array-based and RNAseq-based studies. This may be related to
platform differences, for example, hybridisation in arrays is less sensitive than high-depth sequencing
and potentially affected by differing background signals in various tissues. Differences between
the study populations being compared can also give rise to imperfect validation and also to novel
discoveries, as all genetic effects depend on both the genetic (epistasis) and environmental context of
the population they were estimated in and, therefore, do not necessarily apply to another population or
the same population at a different time. A more accurate way of identifying novel eQTL in this study
would have been to contrast PAH eQTL effects with eQTL effects estimated in a control population
assayed on the same platforms and in one batch with the PAH samples to reduce the variability due to
technical factors. In addition, novel eQTL are yet to be replicated in an independent population of
PAH patients to identify true positives.
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The effects of eQTL can vary by the tissue and even cell type under investigation [28,38] and
may be modified by external and environmental factors [29,30]. Previous studies have successfully
identified ‘response’ eQTL that are associated with gene expression levels in cells under one of
two experimental conditions, but not both. For example, in the study of Barreiro, nearly 200 eQTL
were identified in primary dendritic cells from 65 individuals with effects specific to either the
Mycobacterium tuberculosis-infected cells or the uninfected ones [29]. These response eQTL were
argued to constitute natural regulatory variation that likely affect host-Mycobacterium tuberculosis
interaction and account for interindividual variation in the immune response and susceptibility of
tuberculosis. The authors of the study found when integrating their data with genome-wide genetic
susceptibility of pulmonary tuberculosis that these response eQTL were more likely to be associated
with the disease, uncovering potential susceptibility genes in pulmonary tuberculosis. Another study
by Fairfax et al. [30] investigated the effect of innate immune stimuli on eQTL effects by exposing
primary CD14+ cells from 432 European volunteers to the inflammatory cytokine interferon-γ or
the endotoxin lipopolysaccharide. Inflammatory stimulation revealed hundreds of eQTL specific to
either stimulus, which were enriched for disease-risk loci. In this study, the proportion of eQTL also
associated with lung diseases or lung function was twice as high in the novel eQTL subset than in the
confirmed subset, highlighting the importance of genotype-environment interaction in understanding
the genetic variation of disease susceptibility characterised by genome-wide association studies.
To date, large-scale eQTL-mapping has been done in healthy individuals from population-based
studies (Joehanes et al., 2017, Westra et al., 2013, Zhernakova et al., 2017), providing a valuable
knowledge base for understanding associations between genetic variation and various phenotypes.
It has been shown that by recapitulating the environmental context relevant to disease, it is possible
to decipher the genetic variation of disease susceptibility more extensively (Fairfax et al., 2014,
Barreiro et al., 2012, Çalışkan et al., 2015). Genome- and transcriptome-wide eQTL-mapping in
this cohort of idiopathic and heritable PAH patients identified hundreds of potentially novel eQTL
with twice the proportion of lung disease associated with genetic variants than eQTL confirmed by
population-based studies. Apart from pulmonary conditions, these novel eQTL specific to, or active
in, PAH could be useful in understanding genetic risk factors for other diseases that share common
mechanisms with PAH, such as those with immune dysregulation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/11/1247/s1,
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